What’s the story regarding the vaccine in Britain? There’s probably a solid bureaucratic contingent there, assuming the British haven’t been caught with their Brexit pants down in this sector too. I’d guess there’s a significant target population of horses in Britain, considering the size of the market.
1 Like
Google Translate:
"Production of the Strangvac vaccine is already underway in Spain, but we need to print labels, cartons and package leaflets. You can not do that until you have received a permit, says Andreas Andersson, CEO of the veterinary drug company Intervacc. "
From what I’ve followed on the Avanza forum, the British marketing authorization is expected in the next few weeks
Danske Bank’s target price for the company is SEK 110.
4 Likes
Intervacc’s Q2 release has been brought forward from September 3 to August 31. What could be behind such a fine-tuning? Perhaps it’s necessary to release something in August for some unknown reason. One would assume there’s a rational reason for this – i.e., it’s unlikely to be, for example, the CEO’s sun holiday or based on warning messages from a fortune-teller’s tarot cards?
This comes directly from Nasdaq’s rules. Q and semi-annual reports must be published within 2 months. It seems the guys didn’t pay attention to this back in the day.
1 Like
Thanks for the enlightening info. Indeed, August 31st seems to be the last firm in Helsinki as well. I wonder if Intervacc has been so busy with its vaccine for a longer time that it has indeed overlooked the rules of monopoly. By the way, what might be Nasdaq’s sanction for firms that stumble in their reporting beyond such a deadline?
Yesterday, a report was indeed released - nothing world-changing or company-changing in it. Financially, nothing major, but then again, the horse vaccine has only just begun to be transported to the refrigerators of the distribution network. The CEO naturally expressed joy in the report that the development of cow and pig vaccines has also progressed, although no other information about them seems to have emerged from other channels, such as research reports. But there is indeed a strong point in the fact that Intervaccin’s recipe for vaccine preparation has proven its effectiveness and borne fruit - although hardly any of the vaccine concoctions will receive Michelin stars. The share price has withered by over 12% in a month - try to figure out if there are rational reasons for that…
3 Likes
Thanks for the info. Let’s keep an eye on the situation. Earnings growth should be ahead.
1 Like
UK marketing authorization in the section 
8 Likes
Comment on that April news.
BRIEF-Intervacc AB And Dechra Pharmaceuticals Enter Into An Agreement To Commercialize Strangvac In Europe 12th Apr News Dechra Pharm PLC. Dechra has since risen from a little over £32 in April to slightly over £50. Dechra is, of course, a large company with many irons in the fire, but an interesting partner for the small Intervacc company.
A 2021 report by two researchers on Equine strangles: An update on disease control and prevention
https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0719-81322021000100023
Discusses, among other things, the efficacy of various vaccinations, and briefly mentions Strangvac:
The inclusion of immunoglobulin-cleaving proteins IdeE and IdeE2 in subunit vaccines were found to be important for effective protection (Guss et al 2009). A developed vaccine (known as Strangvac), based on a SeM-9 SEE strain isolated in Sweden (Guss et al 2009), included immunoglobulin-cleaving proteins IdeE and IdeE2 but not SeM or SEQ2190 proteins, to reach DIVA properties. The strain used is more closely related to the circulating strains in Europe (UK) and was found to provide protection against in vivo challenge (Guss et al 2009).
The article also briefly mentioned other vaccines, and perhaps the most interesting piece of information was the DIVA (Differentiating Infected from Vaccinated Animals) — that is, distinguishing vaccinated animals from unvaccinated ones. Strangvac has this DIVA property, while others do not. And this is a useful feature, for example, when competing or planning stable placements, it would be possible to differentiate vaccinated animals from each other.
1 Like
Intervacc has received a patent in the USA related to a pig vaccine. A very significant step forward. Of course, a responsible investor may consider whether this also means that the vaccine will promote industrial intensive production of pork.
5 Likes
Q3
“We expect the first doses to be approved and released in time to start sales before the end of the year. To ensure a safe and secure launch, we plan to start with sales in Sweden and then roll out Strangvac® in the rest of Europe.”
CEO video interview in Swedish:
5 Likes
ABG’s latest report (15.11.21)
1 Like
2 Likes
Stock price falling:
"The animal health company Intervacc is losing significant ground after yesterday’s press release stating that the Strangvac vaccine will begin trading in the first quarter of 2022. The stock is currently trading down over 20 percent.
A document from the Swedish Medical Products Agency (Läkemedelsverket) has been circulating on social media. It is dated December 10 and states, among other things, that horses vaccinated with Strangvac can still become infected with strangles and spread it further.
“Strangvac cannot therefore be used to limit and combat infection, and vaccination cannot replace infection control measures to limit the risk of spreading S. equi,” writes the Medical Products Agency.
Major shareholder Hans Isoz, who owns 1.7 percent of the capital, believes that the Medical Products Agency has done a poor job and thus not described Strangvac correctly. At the same time, it is highlighted that the EMA (European Medicines Agency) spent a year and a half reviewing and approving the vaccine, which is stated to provide 94.7 percent protection.
Intervacc initially rose sharply on the stock exchange yesterday afternoon after the announcement of sales launch, but lost most of the gains towards closing.
Finwire is seeking Intervacc’s CEO for a comment."
A dispute about whether the vaccine provides good protection or not, a major shareholder points out that the EMA investigated the matter for 1.5 years and approved the 94.7% vaccine protection claim.
Quite a swing-trade opportunity if one can interpret the situation correctly and make purchases before the company releases a rebuttal, which would likely stabilize the stock price. And, of course, the other side is that if the company is unwilling to comment on the matter, or if the claim has merit, then the stock price could really hit rock bottom.
So, the mess started with this:
https://www.lakemedelsverket.se/sv/behandling-och-forskrivning/lakemedelsmonografier/sok-monografier/strangvac-rekombinanta-proteiner-cce-eq85-och-idee-fran-streptococcus-equi
“Experience has shown that it is difficult to produce vaccines against strangles that can effectively prevent horses from becoming infected, spreading infection, and developing clinical disease. Vaccines therefore do not have a significant place in the management of strangles in Sweden. Horses vaccinated with Strangvac can still become infected, develop clinical disease, and spread the infection further. Strangvac cannot therefore be used with the aim of limiting and combating infection, and vaccination cannot replace infection control measures to limit the risk of spreading S. equi.”
Well, the vaccine does not offer 100% protection, though no one has claimed such, right? Quarantine practices may remain strict, contrary to what the manufacturer has hinted, but no one will leave their horse unvaccinated if the protection is “only” 94% and not 100%?
4 Likes
What a strange case, I haven’t come across anything like it before.
Trading of the entire stock halted
I haven’t owned the company before, but after a quick read, I took a small swing position. However, behind the EMA’s (European Medicines Agency) decisions is such extensive scientific processing that it shouldn’t be possible to challenge it on very flimsy grounds, especially by any smaller entity (cf. the Evo short report case).
Let’s see what happens, it’s peculiar.
3 Likes
A very strange case. However, the EMA has approved the vaccine after extensive research.
And indeed, trading is halted with -36% on the board… what the heck.
Could this be a buying opportunity? It seems like haste and panic.
I don’t know what stories Intervacc has told investors, but the material on the Swedish Medical Products Agency (Läkemedelsverket) website is apparently the same one EMA used to grant Strangvac market authorization. So the vaccine provides some protection, but it’s not perfect.
Today, small investors are surprised that the vaccine doesn’t give 100% protection and are panic selling their shares?
edit.
Where does the claim of 94% protection come from, could someone link the source?
2 Likes
So small investors are under the impression that the vaccine is 100% effective. Rather unrealistic expectations, I’d say - though I admit I’m not familiar with the animal vaccine sector and the range of vaccine efficacy in detail. I base this on the fact that with human vaccines, very few vaccines achieve over 95% protection. And many of those that fall below that are still classified as quite good vaccines. [And the coronavirus has taught almost everyone that an important feature of vaccines is also how long the achieved protective efficacy remains at a constant level].
1 Like